Soblidotin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Soblidotin
Accession Number
DB12677
Type
Small Molecule
Groups
Investigational
Description

Soblidotin has been used in trials studying the treatment of Sarcoma, Lung Cancer, and Unspecified Adult Solid Tumor, Protocol Specific.

Structure
Thumb
Synonyms
Not Available
External IDs
TZT-1027
Categories
UNII
DQC51A0WQH
CAS number
149606-27-9
Weight
Average: 701.994
Monoisotopic: 701.509134897
Chemical Formula
C39H67N5O6
InChI Key
DZMVCVHATYROOS-ZBFGKEHZSA-N
InChI
InChI=1S/C39H67N5O6/c1-13-27(6)35(43(10)39(48)33(25(2)3)41-38(47)34(26(4)5)42(8)9)31(49-11)24-32(45)44-23-17-20-30(44)36(50-12)28(7)37(46)40-22-21-29-18-15-14-16-19-29/h14-16,18-19,25-28,30-31,33-36H,13,17,20-24H2,1-12H3,(H,40,46)(H,41,47)/t27-,28+,30-,31+,33-,34-,35-,36+/m0/s1
IUPAC Name
(2S)-2-[(2S)-2-(dimethylamino)-3-methylbutanamido]-N-[(3R,4S,5S)-3-methoxy-1-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-2-[(2-phenylethyl)carbamoyl]ethyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-N,3-dimethylbutanamide
SMILES
CC[[email protected]](C)[[email protected]@H]([[email protected]@H](CC(=O)N1CCC[[email protected]]1[[email protected]](OC)[[email protected]@H](C)C(=O)NCCC1=CC=CC=C1)OC)N(C)C(=O)[[email protected]@H](NC(=O)[[email protected]](C(C)C)N(C)C)C(C)C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Soblidotin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Soblidotin.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Soblidotin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Soblidotin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Soblidotin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Soblidotin.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Soblidotin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Soblidotin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Soblidotin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Soblidotin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Soblidotin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Soblidotin.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Soblidotin.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Soblidotin.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Soblidotin.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Soblidotin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Soblidotin.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Soblidotin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Soblidotin.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Soblidotin.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
6918315
PubChem Substance
347828881
ChemSpider
5293519

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentSarcomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00826 mg/mLALOGPS
logP4.36ALOGPS
logP4.4ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)12.7ChemAxon
pKa (Strongest Basic)8.03ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area120.52 Å2ChemAxon
Rotatable Bond Count20ChemAxon
Refractivity197.97 m3·mol-1ChemAxon
Polarizability80.46 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Peptidomimetics
Sub Class
Hybrid peptides
Direct Parent
Hybrid peptides
Alternative Parents
Dipeptides / Valine and derivatives / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / N-acylpyrrolidines / Benzene and substituted derivatives / N-acyl amines / Tertiary carboxylic acid amides / Trialkylamines / Secondary carboxylic acid amides
show 6 more
Substituents
Hybrid peptide / Alpha-dipeptide / N-acyl-alpha amino acid or derivatives / Valine or derivatives / Alpha-amino acid amide / Alpha-amino acid or derivatives / N-acylpyrrolidine / Monocyclic benzene moiety / Fatty amide / Fatty acyl
show 24 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:34 / Updated on November 09, 2017 05:11